Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Status:
Recruiting
Trial end date:
2025-12-23
Target enrollment:
Participant gender:
Summary
Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of
combination therapies with adagrasib in patients with advanced NSCLC with TPS ≥ 1% and KRAS
G12C mutation